Pooled estimates of SC to 1 or 2 doses of the pandemic influenza vaccine in patients treated with anti-CD20 therapy
| . | . | . | Pooled estimate of SC, % (95% CI, I2 %) . | |
|---|---|---|---|---|
| Duration of time since last anti-CD20 treatment, mo . | No. of studies . | Total no. of patients . | For 1 vaccine dose . | For 2 vaccine doses . |
| Active, <3 | 6 | 75 | 3 (0-9, 0) | 12 (2-27, 37) |
| 3-6 | 2 | 21 | 21 (0-65, 71) | 4 (0-32, 0) |
| 6-12 | 1 | 12 | 50 (4-96, N/A) | 50 (4-96, N/A) |
| >12 | 2 | 26 | 41 (19-65, 0) | 75 (39-100, 41) |
| . | . | . | Pooled estimate of SC, % (95% CI, I2 %) . | |
|---|---|---|---|---|
| Duration of time since last anti-CD20 treatment, mo . | No. of studies . | Total no. of patients . | For 1 vaccine dose . | For 2 vaccine doses . |
| Active, <3 | 6 | 75 | 3 (0-9, 0) | 12 (2-27, 37) |
| 3-6 | 2 | 21 | 21 (0-65, 71) | 4 (0-32, 0) |
| 6-12 | 1 | 12 | 50 (4-96, N/A) | 50 (4-96, N/A) |
| >12 | 2 | 26 | 41 (19-65, 0) | 75 (39-100, 41) |
N/A, not applicable.